Back to results
US 11,299,738 B2Granted
Further novel oligonucleotide-ligand conjugates
AssigneeSilence Therapeutics GmbH
InventorsDmitry Samarsky, Christian Frauendorf
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.
Claims23
A compound having the formula I:
- [S—X1—P—X2]3-A-X3—Z (I)
- wherein:
- S represents a saccharide;
- X1 represents C3-C6 alkylene or (—CH2—CH2—O)m(—CH2)2— wherein m is 1, 2, or 3;
- P is a modified phosphate;
- X2 is C1-C8 alkylene;
- X3 represents a bridging unit;
- Z is a nucleic acid;
- the linkage between X3 and Z is a phosphate or thiophosphate;
- and A is a branching unit selected from:
- wherein:
- R1 is hydrogen or C1-C10 alkylene;
- and R2 is C1-C10 alkylene.
10 more elements
Dependencies are inferred from the claim text.